Optellum

Optellum, a UK-based startup, is revolutionizing early diagnosis and treatment of lung cancer using Artificial Intelligence and Machine Learning. The company's mission is to ensure that every lung cancer patient receives the most effective treatment at the earliest possible stage. Their pioneering Clinical Decision Support software, developed by a team of experts from Oxford's computer vision laboratory, analyzes the world's largest clinical dataset to provide personalized diagnosis and treatment recommendations. With a track record of successful innovation and the backing of a renowned Advisory Board, Optellum secured a significant $14.00M Series A investment from a group of esteemed investors including IQ Capital, Black Opal Ventures, Intuitive, Sir Martin & Lady Audrey Wood, Mercia Fund Managers, and St John's College - Oxford, in September 2022. The company's focus on assembling a high-caliber development team, comprising former engineers from leading technology companies and imaging startup veterans, underscores its commitment to the fight against cancer. For further details, visit http://www.optellum.com/.